DESTINY-Breast03 Phase 3 Study Results
Exploratory Biomarker Analysis in BC Cohorts
Cohort 1
HER2+
Cohort 2
HER2-low
Biomarkera
N
ORR, % (n, 95% CI)
N
ORR, % (n, 95% CI)
64.3%
PD-L1 TC ≥ 1%
Low: 28
Low: 13
(18, 44.1-81.4)
46.2%
(6, 19.2-74.9)
100%
50.0%
High: 3
High: 2
(3, 29.2-100)
PD-L1 IC+ ≥ 5%
Low: 17
64.7 %
(11, 38.3-85.8)
Low: 9
(1, 1.3-98.7)
44.4 %
(4, 13.7-78.8)
High: 14
71.4 %
(10, 41.9-91.6)
High: 6
50.0 %
(3, 11.8-88.2)
66.7 %
PD-L1 IC+ ≥ 1%
Low: 12
(8, 34.9-90.1)
Low: 6
33.3 %
(2, 4.3-77.7)
High: 19
68.4 %
(13, 43.4-87.4)
55.6 %
High: 9
(5, 21.1-86.3)
•
•
Biomarker analyses for cohorts 1
and 2 were performed on baseline
new or archival tumor biopsy
tissue
Antitumor activity with T-DXd plus
nivolumab was observed
regardless of PD-L1 IHC status
BC, breast cancer; HER2, human epidermal growth factor receptor 2; IC, immune cell; IHC, immunohistochemistry; ORR, objective response rate; PD-L1, programmed death ligand 1; TC, tumor cell; T-DXd,
trastuzumab deruxtecan.
aVENTANA PD-L1 (SP263) assay.
ESMO BC 2022 #1620 Oral
Daiichi-Sankyo
69View entire presentation